This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Madrigal Pharmaceuticals, Inc.

Drug Names(s): Hsp70 Inducer, STA-4783

Description: Elesclomol is an small-molecule taxane potentiator that induces the expression of heat shock protein 70 (Hsp70) on the surface of tumor cells, which attracts natural killer (NK) immune cells and activates NK-mediated tumor cell killing. Elesclomol also acts within the centrosome to disrupt the organization of the cytoskeletal network and the process of cell division. Elesclomol acts synergistically with taxanes, a commonly used chemotherapeutic class. In preclinical studies, Elesclomol combined with taxanes has shown activity against a range of cancers, including breast, lung, colon, lymphoma, and melanoma.

Deal Structure: In October 2007, GlaxoSmithKline and Synta Pharmaceuticals announced the execution of a global collaboration agreement for the joint development and commercialization of Elesclomol.

Under the terms of the agreement, the companies will share responsibility for development and commercialization of Elesclomol in the US, and GSK will have exclusive responsibility for development and commercialization of Elesclomol outside the US. Synta will receive an upfront cash payment of $80 million. Synta will also be eligible to receive potential milestone payments of up to $135 million for events leading to approval of Elesclomol in metastatic melanoma, further development and regulatory milestones of up to $450 million across various indications and up to $300 million in potential commercial milestone payments based on achieving certain net sales thresholds. Synta will continue to fund all development for metastatic melanoma in the US and the companies will share responsibility and costs...See full deal structure in Biomedtracker

Elesclomol News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug